Aardvark Therapeutics (Nasdaq: AARD) Prices Initial Public Offering to Raise $94.2Mn

2 min read | February 13, 2025 12:42 AM PST | By Team Kalkine Media

Google News:

Aardvark Therapeutics (Nasdaq: AARD) Prices Initial Public Offering to Raise $94.2Mn — Image source: shutterstock

Recent News

Is Public Service (NYSE:PEG) Still Worth Watching After Strong Results...

Is Church & Dwight (NYSE:CHD) Hiding More Value Than Expected?

Is Hyatt Hotels (NYSE:H) Expansion Already Reflected In Market Valuati...

Jones Lang LaSalle (NYSE:JLL): Why Is Market Attention Growing?

Make Kalkine Media
My Trusted Source

Highlights

Aardvark Therapeutics sets IPO price at $16.00 per share, aiming to raise $94.2 million.

Company will trade on Nasdaq Global Select Market under ticker symbol 'AARD' starting February 13, 2025.

Strong underwriting syndicate led by Morgan Stanley, BofA Securities, Cantor, and RBC Capital Markets.

Aardvark Therapeutics (Nasdaq:AARD), a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for metabolic diseases, has announced the pricing of its initial public offering (IPO). The company is offering 5,888,000 shares of common stock at a price of $16.00 per share, with gross proceeds expected to total approximately $94.2 million before underwriting fees and other expenses.

IPO Details and Trading Launch

Aardvark Therapeutics is set to commence trading on the Nasdaq Global Select Market on February 13, 2025, under the ticker symbol 'AARD'. The offering is expected to close on February 14, 2025, subject to customary closing conditions. In addition to the primary offering, the underwriters have a 30-day option to purchase up to 883,200 additional shares at the public offering price. This could further boost the total proceeds from the IPO if exercised.

Underwriting and Syndicate

The IPO is being led by a strong underwriting syndicate, including top-tier investment banks such as Morgan Stanley, BofA Securities, Cantor, and RBC Capital Markets. These banks bring substantial expertise and credibility to the offering, which is expected to garner significant investor attention. Their involvement further strengthens the company's prospects as it begins its public journey.

Use of Proceeds

The proceeds from the IPO will be used to advance Aardvark Therapeutics' clinical development programs, focusing on its small-molecule therapeutics designed to treat metabolic diseases. These funds will help accelerate the company’s research efforts, enabling it to bring promising treatments to market and address unmet needs in the metabolic disease space.

Potential Impact on Shareholders

While the IPO represents a significant milestone for Aardvark Therapeutics, it does come with potential risks for existing shareholders. The issuance of 5,888,000 new shares will result in dilution for current investors. Moreover, should the underwriters exercise their option to purchase an additional 883,200 shares, it would lead to further dilution and increase the overall share count, potentially affecting the value of existing holdings.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.